Kineta announced that it will present new preclinical data on KVA12123, the Company’s anti-VISTA antibody, in acute myeloid leukemia, AML, at the American Association for Cancer Research, AACR, Blood Cancer Discovery Symposium, to be held on March 4-6 in Boston, Massachusetts. Thierry Guillaudeux, Ph.D., Chief Scientific Officer of Kineta, will be presenting the poster.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on KA:
- Kineta to Present New Preclinical Data on its Anti-VISTA Antibody KVA12123 in Acute Myeloid Leukemia at the AACR Blood Cancer Discovery Symposium
- Kineta to Present at Upcoming Investor Conferences
- Kineta Provides Update on its Ongoing Phase 1/2 VISTA-101 Clinical Trial of KVA12123 in Patients with Advanced Solid Tumors
- Kineta provides update on ongoing Phase 1/2 VISTA-101 trial of KVA12123
- Kineta to Participate in the 13th Annual LifeSci Partners Corporate Access Event